<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01987817</url>
  </required_header>
  <id_info>
    <org_study_id>ARC001</org_study_id>
    <nct_id>NCT01987817</nct_id>
  </id_info>
  <brief_title>Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT</brief_title>
  <acronym>ARC001</acronym>
  <official_title>Phase 2 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen Oral Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aimmune Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aimmune Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind placebo controlled study of efficacy and
      safety of characterized peanut oral immunotherapy in peanut allergic individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind placebo controlled study of efficacy and
      safety of characterized peanut OIT in peanut allergic individuals. All eligible subjects will
      receive an escalating dose of CPNA or placebo. Approximately 50 subjects will be randomized
      1:1 to peanut OIT or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects who tolerate at least 300 mg (443 mg cumulative) of peanut protein with no more than mild symptoms at the exit Double Blind Placebo Controlled Food Challenge (DBPCFC)</measure>
    <time_frame>6-9 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>AR101 powder provided in capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study product provided in pull-apart peanut protein capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo powder provided in capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo formulation in pull-apart capsules containing only inactive ingredients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AR101 powder provided in capsules</intervention_name>
    <description>Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol</description>
    <arm_group_label>AR101 powder provided in capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo powder provided in capsules</intervention_name>
    <description>Study product formulated to contain only inactive ingredients for use as defined in the protocol</description>
    <arm_group_label>Placebo powder provided in capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 4 through 26 years

          -  Clinical history of allergy to peanuts or peanut containing foods

          -  Serum IgE to peanut &gt;0.35 kU/L (determined by UniCAP within the past 12 months) and/or
             a SPT to peanut &gt;3 mm compared to control

          -  Experience dose-limiting symptoms at or before the 100mg dose of peanut protein
             (measured as 200 mg of peanut flour) on abbreviated screening OFC conducted via
             PRACTALL guidelines

          -  Use of birth control by females of child bearing potential

        Exclusion Criteria:

          -  History of Cardiovascular disease

          -  History of frequent or repeated, severe or life-threatening episodes of anaphylactic
             shock

          -  History of other chronic disease

          -  History of eosinophilic gastrointestinal disease

          -  Severe asthma

          -  Mild or moderate asthma if uncontrolled

          -  Use of omalizumab within the past 6 months or current use of other non-traditional
             forms of allergen immunotherapy

          -  Use of beta-blockers(oral), angiotensin-converting enzyme (ACE)

          -  Pregnancy, lactation

          -  Having the same place of residence as another study subject

          -  Participation in an interventional clinical trial 30 days prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerome G. Pinkett,, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Director, Clinical Operations</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2013</study_first_submitted>
  <study_first_submitted_qc>November 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2013</study_first_posted>
  <disposition_first_submitted>June 16, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>June 21, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 23, 2016</disposition_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Characterized Peanut Allergen</keyword>
  <keyword>Peanut</keyword>
  <keyword>OIT</keyword>
  <keyword>Oral Desensitization</keyword>
  <keyword>Peanut Allergen</keyword>
  <keyword>Allergy</keyword>
  <keyword>Peanut Allergy</keyword>
  <keyword>Peanut-Allergic Children</keyword>
  <keyword>Children</keyword>
  <keyword>Peanut-Allergic Adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

